Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
8275157
Reference Type
Journal Article
Title
Cancer and inhibition of fatty acid oxidation
Author(s)
Huqi, A
Year
2011
Issue
51
Page Numbers
27-30
Language
English
Abstract
Recently, a "metabolic transformation" property with increased glycolytic rates (Warburg effect) was described for cancer cells. It has been shown that there is an active interaction between mutations of crucial enzymes involved in metabolic pathways and of oncogenes, whose effector proteins also exert metabolic functions. Interestingly, because many of these metabolic changes are confined to the mutant clones, targeted therapy appears very promising in terms of both safety and efficacy. Pharmacological inhibition of glycolysis by dichloroacetate (DCA) significantly inhibits proliferation of cancer cells. However, because of the pharmacokinetic characteristics, the plasma concentration levels and, therefore, toxic effects (i.e., hepatotoxicity and neurotoxicity) of DCA are difficult to predict. Similar metabolic modulation and antiproliferative effects can be obtained through inhibition of fatty acid oxidation. Such agents have been safely used in other clinical conditions such as heart disease and, as such, deserve further testing in cancer therapy.
Keywords
Cancer; Fatty acid oxidation; Metabolic modulation therapy; Warburg effect
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity